Vulvodynia Treatment Market Size, Share, Trends (2022-27)
Market Overview:
Over the forecast period, the market for vulvodynia treatment is anticipated to experience a CAGR of nearly 9%. (2022–2027).
The market for vulvodynia treatments has been significantly impacted by the COVID-19 pandemic, an unprecedented health threat. The COVID-19 pandemic has posed significant challenges for clinical practise, frequently delaying the management of patients with treatable conditions, including urogynecological conditions, according to a February 2022 article titled “Vulvodynia associated with vulvovaginal microbiome: Neglected due to the COVID-19 pandemic?”. Such studies reveal that vulvodynia treatment visits decreased during the pandemic, illustrating a short-term detrimental effect on the market. However, the market is anticipated to exhibit healthy growth in the upcoming period due to the introduction of vaccines and the strengthening of lockdown restrictions.
Scope of the Report:
As per the scope of this report, vulvodynia, or pain in the vulva, is a chronic condition characterized by burning, stinging, and stabbing sensations. The treatment for vulvodynia includes avoiding irritants such as tight-fitting clothing, perfumes, and dyes, as well as medications such as local anesthetic and nerve medication, among other medications. The market is segmented by drug type (local anesthetics, anticonvulsants, tricyclic antidepressants, antimicrobials, and other drug types), by mode of administration (oral, topical, and injectable), by distribution channel (hospital pharmacies, retail pharmacies, and other distribution channels) and geography(North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above-mentioned segments.
Comments
Post a Comment